Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes
Journal of Psychopharmacology January 1, 2022 DOI: 10.1177/02698811211066714
Summary
Lifetime MDMA/Ecstasy use is associated with 16% lower odds of experiencing a major depressive episode. An analysis of 213,437 US adults found MDMA, or Ecstasy, linked to 16-18% lower odds of these episodes. The hallucinogen Psilocybin, a classic psychedelic, correlated with 10-13% lower odds. These findings offer intriguing insights for Psychiatry and Medicine, suggesting potential avenues for Psychology in addressing major depressive episodes, unlike other substances examined.
Abstract
Background: Depression is a major mental health issue worldwide, with high rates of chronicity and non-recovery associated with the condition. Existing treatments such as antidepressant medication and psychological treatments have modest effectiveness, suggesting the need for alternative interventions. Aim: The aim of this study was to examine the relationships between MDMA (3,4-methylenedioxymethamphetamine)/ecstasy and psilocybin use and major depressive episodes (MDEs). Methods: This observational study used data from a large ( N = 213,437) nationally representative sample of US adults to test the association of lifetime use of MDMA/ecstasy, psilocybin and other classic psychedelics (lysergic acid diethylamide (LSD), peyote, mescaline), other illegal substances (e.g. cocaine, phencyclidine (PCP)), and legal/medicinal substances of misuse (e.g. pain relievers, tranquilizers) with lifetime, past year, and past year severe MDEs. Results: Results revealed that lifetime MDMA/ecstasy use was associated with significantly lowered odds of a lifetime MDE (adjusted odds ratio (aOR) = 0.84; p < 0.001), past year MDE (aOR = 0.84; p < 0.001), and past year severe MDE (aOR = 0.82; p < 0.001). Psilocybin was associated with significantly lowered odds of a past year MDE (aOR = 0.90; p < 0.05) and past year severe MDE (aOR = 0.87; p < 0.05). All other substances either shared no relationship with a MDE or conferred increased odds of an MDE. Conclusions: These results suggest that MDMA/ecstasy and psilocybin use is associated with lower risk of depression. Experimental studies are needed to test whether there is a causal association between use of these compounds and the alleviation of depressive symptoms.